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Abstract
Exposure assessment is a fundamental part of the risk assessment paradigm, but can often present a number of challenges and 
uncertainties. This is especially the case for process contaminants formed during the processing, e.g. heating of food, since 
they are in part highly reactive and/or volatile, thus making exposure assessment by analysing contents in food unreliable. 
New approaches are therefore required to accurately assess consumer exposure and thus better inform the risk assessment. 
Such novel approaches may include the use of biomarkers, physiologically based kinetic (PBK) modelling-facilitated reverse 
dosimetry, and/or duplicate diet studies. This review focuses on the state of the art with respect to the use of biomarkers of 
exposure for the process contaminants acrylamide, 3-MCPD esters, glycidyl esters, furan and acrolein. From the overview 
presented, it becomes clear that the field of assessing human exposure to process-related contaminants in food by biomarker 
monitoring is promising and strongly developing. The current state of the art as well as the existing data gaps and chal-
lenges for the future were defined. They include (1) using PBK modelling and duplicate diet studies to establish, preferably 
in humans, correlations between external exposure and biomarkers; (2) elucidation of the possible endogenous formation of 
the process-related contaminants and the resulting biomarker levels; (3) the influence of inter-individual variations and how 
to include that in the biomarker-based exposure predictions; (4) the correction for confounding factors; (5) the value of the 
different biomarkers in relation to exposure scenario’s and risk assessment, and (6) the possibilities of novel methodologies. 
In spite of these challenges it can be concluded that biomarker-based exposure assessment provides a unique opportunity to 
more accurately assess consumer exposure to process-related contaminants in food and thus to better inform risk assessment.
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Introduction
Exposure assessment is a fundamental part of the risk assess-
ment paradigm but can often present a number of challenges 
and uncertainties. The science of exposure assessment is 
undergoing fundamental change with the development of 
new approaches that do not just focus on occurrence in food 
and consumption patterns, i.e. on external exposure metrics. 
The advent of metabolomics, picturing the totality of metab-
olite profiles opens up the prospect of collecting compre-
hensive exposure information on specific dietary chemicals 
and their interaction in the body. Another option consists of 
monitoring selected biomarkers in body fluids or tissues as 
quantitative exposure indicators, based on detailed knowl-
edge of the metabolism of the dietary chemical in focus. 
This allows determination of external exposure levels based 
on these biomarkers of internal exposure, as opposed to less 
reliable methods such as food frequency questionnaires.
Deriving accurate exposure estimates for certain con-
taminants in food can be particularly challenging. This is 
especially the case for several process-related contaminants. 
Process contaminants are formed during the processing, e.g. 
heating of food. They can be formed during both home cook-
ing and industrial food manufacturing. Some are known to 
be volatile, e.g. furan, or to bind to food constituents. An 
example of this latter aspect is acrylamide that has been 
shown to bind, depending on storage time and conditions, 
to some degree covalently to insoluble matrix constituents 
of roast and ground coffee thus being no longer bioavail-
able (Baum et al. 2008). Assessing how much of a process 
contaminant such as acrylamide is generated through home 
cooking can also be challenging because these conditions 
are very variable. In the case of furan, preparation steps, 
from cooking food at home and preparation of beverages 
like coffee to processing food samples in the analytical labo-
ratories can have an impact on the levels of furan detected 
in the food or beverage. There is also evidence to suggest 
that acrylamide and other process-related contaminants are 
formed endogenously. Therefore, there are significant uncer-
tainties related to the assessment of consumer exposure to 
process-related contaminants.
Due to these uncertainties, assessing exposure from 
dietary and environmental sources only may underestimate 
the true exposure. New approaches are therefore required 
to accurately assess consumer exposure and thus better 
inform the risk assessment of the exposure to these con-
taminants. Such novel approaches may include use of bio-
markers, physiologically based kinetic (PBK) modelling-
facilitated reverse dosimetry, and/or duplicate diet studies 
and the use of stable isotope labelled marker compounds.
This review focuses on the state of the art with respect 
to the use of biomarkers of exposure for the process 
contaminants acrylamide, 3-MCPD esters, glycidyl esters, 
furan and acrolein. These are all process contaminants of 
public health concern that have undergone or are under-
going safety assessments by risk assessment bodies such 
as the European Food Safety Authority (EFSA) or the 
Joint FAO/WHO Expert Committee on Food Additives 
(JECFA). These compounds have the potential to impact 
public health based on risk assessments indicating low 
safety margins between human exposure and adverse effect 
levels observed in animal studies. Risk assessments pre-
pared on acrylamide by the EFSA and the JECFA indicate 
the need for more accurate exposure estimates utilizing 
biomarkers. In its assessment of acrylamide in food JECFA 
recommended that, in longitudinal studies of acrylamide 
and glycidamide, haemoglobin adducts are measured over 
time in relation to concurrent dietary exposures (JECFA 
2011). EFSA recommended that in order to improve the 
exposure assessment of acrylamide duplicate diet studies 
be conducted and that data on urinary metabolite levels 
be collected from individuals participating in such studies 
for the purpose of validating the biomarkers (EFSA 2015). 
Because of its volatility, establishing accurate estimates of 
exposure to dietary furan will be difficult and associated 
with a large amount of uncertainty. Acrolein is formed dur-
ing cooking, particularly when oil is overheated. It can be 
found in fried food, cooking oil and roasted coffee (lARC 
1993). Contents in food are often determined by headspace 
techniques which, however, only measure the volatile pro-
portion of acrolein. Because of its high Michael reactiv-
ity, acrolein is supposed to rapidly react with nucleophilic 
food constituents, including water, forming non-volatile 
acrolein adducts (Abraham et al. 2011) Moreover, acryla-
mide and acrolein are also formed endogenously within 
the body (Uchida et al. 1998; Stevens and Maier 2008; 
Goempel et al. 2017) and therefore make interesting case 
studies on how to differentiate between exposure from 
exogenous and endogenous sources. Duplicate diet stud-
ies are promising since they allow to exactly measure the 
dietary intake of a given process related contaminant and 
to compare this with the urinary output of appropriate 
metabolites that allow biomarker-based dosimetry. This, 
however, may not be helpful in the case of acrolein unless 
methods become available to comprehensively analyse free 
acrolein together with that reversibly bound to food matrix 
constituents.
The review shortly introduces how and where these pro-
cess contaminants are formed and their potential impact on 
human health. Then the current knowledge on urinary, blood 
and tissue biomarkers for each of these contaminants is sum-
marized and where available, PBK models are discussed. 
The potential for endogenous formation of these process 
contaminants is also considered. There are clearly data gaps 
for most of these process contaminants that would need to be 
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addressed in order to provide reliable and reproducible quan-
titative estimates of exposure via the use of their biomarkers. 
Ultimately the aim would be to incorporate such quantitative 
exposure estimates into risk assessment to better define the 
public health risk and inform risk management action.
State of the art
Acrylamide
Characterization, formation, occurrence and public health 
concern
Acrylamide (AA) is a large volume industrial chemical used 
as monomeric building block in the production of poly-
acrylamides. For analytical purposes it serves worldwide 
for in situ preparation of polyacrylamide gels in biochemi-
cal laboratories. In 2002, AA surprisingly was reported by 
Swedish scientists to be present in many commonly con-
sumed foods as a result of heat treatment (Rosén and Hel-
lenäs 2002). AA is a process related food contaminant gen-
erated during various food heating processes from reducing 
carbohydrates and asparagine. Due to the natural presence 
of these precursor constituents in foods, the most important 
mechanism of AA formation in foods appears to result from 
the heat induced reaction of such precursors in the course 
of Maillard reactions governing food browning, involving 
the intermediate formation of 3-aminopropionamide and its 
equivalents. As a consequence, substantial AA contamina-
tion has consistently been found in strongly heated carbo-
hydrate-rich foods such as French fries and potato chips or 
crisps, and roasted coffee beans (Guth et al. 2013; EFSA 
2015). In lipid-rich food the route of AA formation via acr-
olein and ammonia may also play some role, as acrolein is 
formed in substantial amount from glycerol and mono-acyl-
glycerols upon heating of animal and vegetable fats (Umano 
and Shibamoto 1987; Gertz and Klostermann 2002; Yasu-
hara et al. 2003).
AA has been classified by the International Agency for 
Research on Cancer (IARC) (IARC 1994) as genotoxic and 
probably carcinogenic to humans (group 2A). Dietary expo-
sure of adults in Europe has been estimated at the 95th per-
centile between 0.6 and 2.0 µg/kg body weight (bw)/day and 
for children between 1.4 and 3.4 µg/kg bw/day (EFSA 2015).
EFSA calculated margins of exposure (MOE) ranging 
from 283 to 50 for the 95th percentile average exposure 
estimates, based on a benchmark dose lower confidence 
limit (BMDL10) of 0.17 mg/kg bw/day. This BMDL10 
was deduced from a 2-year National Toxicology Program 
(NTP) dose–response study in male B6C3F1 mice, taking 
Harderian gland neoplasms as the critical neoplastic lesion. 
Based on this rather low MOE range resulting from the 
above exposure estimates, EFSA expressed a human health 
concern with respect to neoplastic effects (EFSA 2015). No 
concern was expressed with respect to neurotoxicity or other 
adverse effects potentially associated with dietary exposure 
to AA. However, the relevance of genotoxic efficacy of AA 
to cancer endpoints observed in animals is under continu-
ous scrutiny. For instance the plausibility of hypothesized 
modes of action (MOAs) of AA causing thyroid (but not 
liver) tumours in rats, namely genotoxicity/mutagenicity 
versus thyroid hormone dysregulation, was tested in F344 
rats at dosages of up to 12.0 mg/kg bw/day for different 
subchronic time periods. Differently expressed genes in both 
tissues provided at best marginal support for hormonal and 
genotoxic MOAs. Instead, pronounced effects on calcium 
signalling/cytoskeletal genes were seen in the thyroid target 
organ, suggesting perturbation of calcium signalling as a 
novel MOA for AA mediated thyroid carcinogenicity in the 
male rat (Chepelev et al. 2017). A similar MOA has also 
been evidenced as probably causative for tumour induction 
in another target organ of AA, the rat testes, under the same 
experimental conditions (Recio et al. 2017). Differential 
mutagenicity studies in the micronucleus (MN) and Pig-a 
gene mutation assays in F344 rats and B6C3F1 mice, per-
formed under similar experimental conditions, revealed neg-
ative or equivocal results, except for MN induction in mice, 
supporting structural DNA damage but not point mutations 
as MOA underlying genotoxicity. Moreover, a lack of in vivo 
genotoxicity observed at dosages < 6.0 mg/kg/day was found 
consistent with the notion that non-genotoxic mechanisms 
contribute to AA induced carcinogenicity in rodents (Hobbs 
et al. 2016).
Urinary biomarkers
AA is rapidly absorbed from the gastrointestinal tract and 
undergoes fast systemic distribution and extensive bio-
transformation. It reacts with plasma and other proteins, 
preferably at nucleophilic thiol or amino groups and also 
is efficiently coupled to glutathione (GSH) during first 
pass metabolism in the liver. Importantly, it undergoes 
cytochrome P450 2E1-dependent conversion into the ulti-
mate genotoxic metabolite 2,3-epoxypropanamide or glycid-
amide (GA) (Fig. 1). Interspecies differences, dose depend-
encies and impact of linear versus nonlinear effects result in 
differences in epoxidation of AA to GA (Gargas et al. 2009). 
Like AA, GA avidly forms covalent adducts with proteins 
and GSH but may also react with DNA, generating DNA 
adducts, preferentially at N7 of deoxyguanine forming a 
depurinating guanosine adduct (N7-GA-Gua) (Fig. 1). Thus, 
GA formation and its reaction with DNA are conceived as 
the key events underlying genotoxicity and carcinogenic-
ity of AA (EFSA 2015). The primary glutathione conju-
gates of AA and GA (AA-GSH and GA-GSH) are further 
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metabolically processed, mainly in the kidney and urinary 
tract and excreted in urine as AA- and GA-related mercap-
turic acids (MA), N-acetyl-S-(2-carbamoylethyl)-l-cysteine 
(AAMA), N-(R,S)-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-
l-cysteine (GAMA), and N-(R,S)-acetyl-S-(1-carbamoyl-
2-hydroxyethyl)-l-cysteine (iso-GAMA) (Hartmann et al. 
2009). Humans were found to also excrete a sulfoxide of 
AAMA (AAMA-sul), to an extent comparable to GAMA 
(Wang et al. 2017).
In primary rat hepatocytes the rate of AA-GSH adduct 
formation was found to be up to 3 times higher than the 
formation of the genotoxic epoxide GA under low exposure 
conditions (2 µM AA in the incubation medium, mimick-
ing worst case consumer exposure) (Watzek et al. 2012a). 
Urinary AAMA and GAMA have proven useful as valid 
biomarkers for AA exposure (Bjellaas et al. 2005, 2007; 
Boettcher et al. 2005; Kellert et al. 2006; Urban et al. 2006). 
Studies on toxicokinetics of AA in humans report roughly 
half of an ingested AA dose to be eliminated as AAMA, 
whereas 5–6% is excreted in the urine as GAMA (Boettcher 
et al. 2006; Fennell et al. 2006; Fuhr et al. 2006; Hartmann 
et al. 2008). The kinetics of mercapturic acid excretion in 
urine after AA exposure shows AAMA/GAMA to be rapidly 
formed in humans and excreted nearly quantitatively within 
72 h (Ruenz et al. 2016). Monitoring of urinary AAMA/
GAMA therefore is ideally suited to assess controlled short-
term exposure as executed in dietary intervention studies. 
For such studies, duplicate diet methodology has been 
recommended as the method of choice to achieve exactly 
controlled dietary AA intake under controlled conditions 
(EFSA 2015; Ruenz et al. 2016). This methodology enables 
reliable dosimetry of the AA ingested by the study volun-
teers because AA contents are measured in duplicates of 
the prepared meals on the plate. Thus correlations between 
controlled dietary AA exposure and biomarker kinetics 
can be investigated under realistic conditions (Ruenz et al. 
Fig. 1  Biotransformation of AA and biomarkers of AA expo-
sure including the AA- and GA-related urinary mercapturic acids, 
N-acetyl-S-(2-carbamoylethyl)-l-cysteine (AAMA) and N-(R,S)-
acetyl-S-(2-carbamoyl-2-hydroxyethyl)-l-cysteine (GAMA), N-(R,S)-
acetyl-S-(1-carbamoyl-2-hydroxyethyl)-l-cysteine (iso-GAMA), and 
N-(2-carbamoylethyl)valine (AA-Val) and N-(2-carbamoyl-2-hydrox-
yethyl)valine (GA-Val) reflecting Hb adduct formation, as well as 
the formation of depurinating DNA adducts by GA at N7 of guanine 
(N7-GA-Gua)(major) and N3 of adenosine (N3-GA-Ade)(minor). 
The human metabolite AAMA Sulfoxide (AAMA-sul) is not indi-
cated
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2016; Goempel et al. 2017). Monitoring the urinary AAMA/
GAMA excretion rates can inform about the balance within 
the individual metabolic setup governing AA detoxification 
by direct or glutathione S-transferase-mediated GSH cou-
pling and AA toxification by phase I epoxidation to GA, 
because the latter is, similar to AA, also subject to subse-
quent phase II biotransformation into GAMA.
Blood biomarkers
During their systemic distribution and biotransformation AA 
and GA react with nucleophilic sites throughout the body. 
In blood, a major reaction consists in formation of covalent 
adducts with amino and thiol groups of haemoglobin (Hb). 
The Hb-adducts, N-(2-carbamoylethyl)valine (AA-Val) and 
N-(2-carbamoyl-2-hydroxyethyl)valine (GA-Val) (Fig. 1) can 
specifically be determined with a modified Edman degrada-
tion of the alkylated N-terminal valine and a subsequent 
acetonization of the glycidamide-valine pentafluorophe-
nylthiohydantoin derivative for determination by GC/MS 
analysis (Paulsson et al. 2003a). More recently, an alter-
native method using liquid chromatography–tandem mass 
spectrometry (LC–MS/MS) for simultaneous determination 
of AA-Val and GA-Val has been reported (Von Stedingk 
et al. 2010). This rapid and very sensitive variant of the 
Edman procedure uses fluorescein isothiocyanate (FITC) as 
a novel Edman reagent. Prior to LC-MS/MS analysis the two 
fluorescein thiohydantoin derivatives of AA-Val and GA-
Val are enriched and purified on SPE mixed mode anion 
exchange cartridges (Von Stedingk et al. 2010). Hb-adduct 
monitoring is considered a valuable method to assess the 
internal burden associated with longer term AA exposure, 
reflecting the exposure over the last 4 months, since the aver-
age lifespan of human erythrocytes is 120 days (Schettgen 
et al. 2004; Vesper et al. 2006; Goempel et al. 2017).
In laboratory animals GA-haemoglobin adduct concentra-
tions have been reported to correlate with GA-DNA adduct 
levels found in the liver and therefore Hb-adducts have been 
proposed as surrogate biomarkers for DNA adduct forma-
tion (Tareke et al. 2006; Angerer et al. 2008; Hartmann et al. 
2008). However, the correlation between GA-Hb-adducts 
and DNA adduct formation observed in animal experiments 
may not hold for low exposure situations close to human 
dietary intake levels. For instance, in Sprague Dawley rats 
ingesting AA (100 µg/kg bw/day) for 9 days in their feed, the 
biomarker response clearly indicated metabolic formation of 
GA as reflected by excretion of AAMA and GAMA (urinary 
GAMA/AAMA ratio about 0.5–1.1). However, Hb-adducts 
behaved quite differently: whereas there was a distinct cumu-
lative formation of AA-Val over the whole exposure period, 
the biomarker indicative for GA in the blood did not devi-
ate significantly from background. This suggested that any 
GA formed during first pass in the liver of these rats was 
efficiently GSH-coupled and detoxified. Indeed, GA was 
barely detectable in the blood (Cmax < 0.06 µM), whereas 
AA reached substantial blood levels (0.5–2 µM) after intake 
from feed or water (Berger et  al. 2011). The behaviour 
observed for GA-Hb-adducts would suggest that signifi-
cantly enhanced genotoxicity may not be expected during 
first pass at this relatively low exposure level. This corol-
lary was substantiated later by results of a dose–response 
study in rats with single oral AA doses of 0.1–10 000 µg/
kg bw with monitoring excretion of urinary AAMA/GAMA 
and formation of N7-GA-Gua adducts in different organs. In 
the low dose range (0.1/1.0/10/–100 µg/kg bw) DNA adduct 
levels did not show linear dose dependence and remained in 
a very low background range, not exceeding 2 adducts/108 
nucleotides (Watzek et al. 2012b).
In a human biomarker monitoring study, 45 males and 46 
females of the general population (aged from 6 to 80, median 
36 years) were analysed simultaneously for Hb-adducts and 
urinary AAMA/GAMA. For Hb-adducts, the ratio between 
GA-Val and AA-Val was found individually highly variable 
(range 0.4–2.7, median 1.1) and roughly in a similar range 
as reported in a series of other international studies (0.5–1.1, 
median levels) (Hartmann et al. 2008). In laboratory ani-
mals, ratios of 1.8 for rats and of 5.4 for mice were reported, 
respectively, as compared to 1.0 for humans (Paulsson et al. 
2003b). This indicates considerably higher rates of activat-
ing biotransformation of AA to GA in mice as compared to 
rats or humans. This conclusion was substantiated in later 
studies at a higher dose range (Tareke et al. 2006). The ratio 
of AA-Val to GA-Val after oral application of 50 mg/kg bw 
to rats was reported to be 0.38 (Sumner et al. 2003). By 
comparison, the ratio found in humans after intake of 0.5, 
1.0, and 3 mg/kg AA was between 0.36 and 0.44 (Fennell 
et al. 2004).
Tissue biomarkers
Theoretically, in tissues covalent coupling of AA and GA to 
structural proteins may be exploitable for assessment of tis-
sue exposure. However, adequate methodology has not been 
developed yet. An alternative approach lies in the determina-
tion of DNA lesions resulting from covalent binding of GA 
to DNA bases. In adult mice, the formation of glycidamide-
guanine DNA (N7-GA-dG) adducts was found to represent 
by far the major type of DNA lesion, whereas glycidamide-
adenosine DNA (N3-GA-Ade) adducts were detected as 
minor DNA lesion (2 orders of magnitude lower). Data 
were reported for liver, lung, and kidney after treatment 
with 50 mg AA/kg bw (Gamboa da Costa et al. 2003). The 
formation of N7-GA-dG adducts (1 adduct/108 nucleotides) 
in liver of Fischer 344 rats given single oral doses of 100 μg/
kg bw in drinking water (gavage) or via diet has also previ-
ously been reported (Doerge et al. 2005). In an extended 
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dose–response study in female Sprague Dawley rats in vivo, 
formation of N7-GA-dG was measured 16 h after oral dos-
age of AA (0.1–10 0000 μg/kg bw) which was previously 
ascertained to represent Tmax of N7-GA-dG levels in all tis-
sues analysed (Watzek et al. 2012b). Background exposure 
to AA was minimized by applying, for 20 days before start 
and throughout the study, an experimental diet with an AA 
content of < 0.5 µg/kg. Urinary GAMA and AAMA were 
monitored at the same time point where N7-GA-Gua dosim-
etry was carried out, although at 16 h, formation and excre-
tion of GAMA and AAMA were not yet complete, reaching 
a mean of 37.0 ± 11.5% of a given AA dose, with a GAMA/
AAMA ratio of 0.4 ± 0.1. This ratio remained constant over 
the whole dose range with no indication of a dose-related 
shift.
At a dose of 1 μg AA/kg bw, the formation of N7-GA-dG 
adducts became detectable in kidney and lung (each with 
p < 0.001) but not in liver. At a 10-fold higher dose (10 μg/
kg bw), adduct levels remained at the same low level, with 
0.4, 1.1, and 0.7 N7-GA-dG/108 nucleotides, respectively, 
in liver, kidney, and lung. At the next higher dose (100 μg/
kg bw) increased adduct levels (p < 0.001) in all organs were 
measured but this increase was not dose related in a linear 
fashion, remaining at a very low level (≤ 2 N7-GA-dG/108 
nucleotides). Altogether, within the above low exposure 
range adduct formation up to 100 µg AA /kg bw was not 
linearly dose related and did not exceed a level of about 2 
N7-GA-dG/108 nucleotides. Conversely, in the higher dose 
range adduct levels were clearly dose dependent (Watzek 
et al. 2012b).
These experimental results may be put into perspective by 
comparison with background levels of DNA lesions reported 
for human tissues. For instance, 7-(2′-carboxyethyl)-dG, an 
adduct chemically similar to N7-GA-dG may arise from 
exposure to acrolein/acrylic acid. A level of 7.5/108 nucle-
otides was measured in human liver (Cheng et al. 2010). 
Another comparison relates to human background levels of 
another structurally related N7 adduct, 7-(2-hydroxyethyl)-
dG, considered to result predominantly from endogenous 
generation of ethane and ethylene oxide and the interaction 
of the latter with DNA. For human lymphocytes and liver 
tissue, levels of 48–58 adducts/108 nucleotides have been 
reported (Wu et al. 1999). It needs to be ascertained whether 
indeed the above group of N7 adducts (and potentially 
some others) is comparable in terms of biological activi-
ties, thus potentially providing a perspective of grouping 
them together in a read across approach. It may be concluded 
here that single oral AA application in the dose range up to 
100 µg/kg bw to rats resulted in tissue adduct levels consid-
erably lower than reported for human background levels of 
structurally related N7-dG adducts.
Available PBK studies
In a model developed for AA, GA and their glutathione 
conjugates, including Hb-adducts and DNA adducts (liver), 
serum AA and GA levels were combined with urinary 
elimination levels for all components from rats and mice 
and simulated from intravenous and oral administration of 
100 µg/kg AA or 120 µg/kg GA. Adduct formation and deg-
radation rates were determined from 6 weeks exposure to 
approximatively 1 mg/kg AA in drinking water, followed by 
subsequent 6 weeks non exposure. In brief, simulations were 
performed based on exposure and elimination data available 
at that time from the literature (Fennell et al. 2004; Fuhr 
et al. 2006) in combination with data on AA and GA-Hb-
adduct levels associated with “background” dietary expo-
sure to AA in the general human population (Boettcher et al. 
2005) to estimate human dietary exposure doses and associ-
ated human liver GA-DNA adduct levels. Human dietary 
“background” exposure was estimated by this approach to 
be about 0.2 µg/kg AA. This exposure was predicted to be 
associated with a steady-state human liver DNA adduct level 
of about 0.06–0.26/108 nucleotides of GA-DNA adducts 
(Young et al. 2007).
In another study, the relationship between the toxifying 
and detoxifying (termed “oxidative” and “reductive”, respec-
tively) metabolic pathways of acrylamide (AA) in the non-
smoking general population was investigated by simultane-
ously monitoring Hb-adducts in blood and GAMA/AAMA 
in the urine (Hartmann et al. 2008). The biomarker levels 
were used to calculate the daily AA intake. In brief, on the 
basis of the AA-Val concentrations in relation to the adduct 
formation reaction rate constant, (k = 4.4 × 10−6 L g of 
 globin−1  h−1) and the mean erythrocyte lifespan (120 days), 
the value for the area under the curve (AUC) of each person 
was calculated. This was multiplied by the elimination rate 
constant (Ek) in humans of 0.15 h−1 (Calleman 1996) and 
the volume of distribution (VD) of 0.38 L/kg (Fennell et al. 
2004). This allowed to calculate an estimate of the daily 
intake of AA, in a similar way as already approached in 
earlier studies (Calleman 1996; Schettgen et al. 2003).
In a comprehensive study in non-smoking postmenopau-
sal female controls from nested ovarian and endometrial 
case-control studies investigated within the EPIC cohort 
(416 and 386 controls, respectively), the median (25th–75th 
percentile) estimated dietary AA intake was 0.3 (0.2–0.5) 
μg/kg bw/day and the median AA-Hb and GA-Hb adduct 
levels were 41.3 (32.8–53.1) and 34.2 (25.4–46.9) pmol/g 
of Hb, respectively, at baseline. A moderate proportion of 
acrylamide adduct variation, in terms of the ratio of GA-Hb/
AA-Hb could be ascribed to alcohol intake and body mass 
index [never versus ever drinkers, p value < 0.0001; < 25, 
25 to < 30 (Obón-Santacana et al. 2017)].
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On the basis of the above model a median daily intake 
of 0.43 μg/kg bw/day (range 0.21–1.04 μg/kg bw/day) was 
calculated. Of note, according to this model, children were 
calculated to ingest 1.3–1.5 times more AA per kilogram of 
body weight than adults. Also, the GAMA/AAMA ratio was 
found to be significantly higher in the group of young chil-
dren (6–10 years) with a median level of 0.5. Gender-related 
differences in internal exposure and metabolism were not 
observed. The latter finding was subsequently confirmed by 
a study that likewise did not find internal exposure to acryla-
mide, as monitored by Hb-adducts, to be affected by gen-
der (Vesper et al. 2010). In contrast, in Chinese adolescents 
(about 100 college students) faster urinary excretion kinetics 
of AAMA (T1/2 = 12.3 h and Cmax = 1973.4 nmol/g urinary 
creatinine) in women as compared to men (T1/2 = 20.0 h and 
Cmax = 1044.7 nmol/g urinary creatinine) was observed. In 
addition, higher Cmax and AUC values of all GAMA and 
AAMA metabolites in urine of normal weight subjects 
(BMI < 24) have been found, as compared to those with 
higher BMI (Wang et al. 2017).
Endogenous formation and accompanying levels 
of the biomarkers
Some observations from human studies appeared to indicate 
higher daily intake estimates of acrylamide based on Hb-
adduct levels as compared to estimates from dietary ques-
tionnaires (Tareke et al. 2008). It was thus hypothesized that 
the Maillard reaction between reducing carbohydrates and 
asparagine also takes place endogenously under physiologi-
cal conditions. To some extent, this may contribute to endog-
enous acrylamide generation (Mottram et al. 2002; Stadler 
et al. 2002; Baynes et al. 2005). Another potential pathway 
of endogenous AA formation was suggested by the finding 
of increased acrylamide and GA-Hb adduct levels in mice 
treated with chemicals that induced oxidative stress. Based 
on this observation it was hypothesized that acrylamide 
may also be formed to some extent as a result of oxidation 
(Tareke et al. 2008).
The assumption of an endogenous AA background was 
substantiated by observations in animal experiments and in 
human intervention studies under tightly controlled condi-
tions. For instance, in an extended dose–response study, rats 
were held under environmental and dietary conditions of 
minimized AA exposure for 20 days before the onset of the 
experiment and throughout the whole study. In the untreated 
controls a background urinary excretion of about 0.8 nmol 
(cumulative excretion 16 h post-application) of GAMA and 
AAMA was consistently found, equivalent to an internal 
exposure estimate of about 1.6-2 nmol (0.6–0.7 μg/kg bw) 
of ingested AA. This was considerably more than was to be 
expected from an assumed worst case AA intake via low 
levels in the feed of 0.4 nmol AA per day (0.1 μg/kg bw) 
(Watzek et al. 2012a). Furthermore, a human intervention 
study was performed with 14 healthy male volunteers over 
a period of 9 days, under controlled conditions, minimiz-
ing any inadvertent AA exposure. Dietary exposure to AA 
was measured by determining AA contents in duplicates of 
all meals consumed. The study design included an initial 
washout period of 3 days on AA-minimized diet, resulting 
in dietary AA exposure not exceeding 41 ng/kg bw/day. At 
the end of the initial 3-day washout period, an AAMA base-
line level of 93 ± 31 nmol/day was recorded. Assuming 30% 
of AA excreted within 24 h as AAMA, this would suggest 
a baseline endogenous exposure level to AA (on washout 
day 2) equivalent to 0.2–0.3 μg AA/kg bw/day exogenous 
exposure (Ruenz et al. 2016). A subsequent duplicate diet 
study was undertaken to confirm this finding and to also 
address the question whether it can be attributed indeed to 
endogenous background AA exposure in humans or whether 
delayed AAMA release from some deep compartment may 
play a role (e.g. by potential cleavage from some structural 
or plasma protein). To this end an extended duplicate diet 
study, encompassing washout periods of up to 13 days was 
carried out in 12 human volunteers. Half of the volun-
teers (n = 6) ingested 13C3D3-AA (1 µg/kg bw), the other 
half consumed freshly prepared meals with exactly known 
AA content by duplicate analysis. At the end of the 13-day 
washout period the 13C3D3-AA group excreted an unlabelled 
AAMA baseline level of 0.14 ± 0.10 µmol/day, although AA 
intake was only about 0.06 µmol/day. This sustained over-
proportional AAMA background indicated an endogenous 
AA baseline exposure level of 0.3–0.4 µg/kg bw/day. The 
excretion of 13C3D3-AA was practically complete within 
72–96 h, thus ruling out delayed release of AA (or any other 
GAMA/AAMA precursor) from deep body compartments. 
These results provide compelling support for the hypothesis 
of a sustained endogenous AA formation in the human body 
(Goempel et al. 2017).
Data gaps and research needs
The database on dietary AA exposure and its association 
with urinary and/or blood exposure biomarkers needs to be 
substantiated to the extent to provide a solid basis for reverse 
dosimetry of dietary AA exposure. This should also encom-
pass an in depth characterization of inter-individual vari-
ance in expression and activity of relevant biotransforma-
tion enzymes, under due consideration of polymorphisms as 
well as age and gender-related variances. Such studies will 
require tightly controlled conditions of dietary AA expo-
sure, as exemplified by duplicate diet studies. Short-term 
biomarkers like urinary GAMA and AAMA and their ratio 
(GAMA/AAMA) appear to be most appropriate. Hb-adducts 
are known to reflect factors of influence associated with 
long term exposure. Since Hb-adducts have been proposed 
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as surrogate markers for genotoxicity of GA, it will be of 
great importance to further investigate whether this surro-
gate biomarker function indeed holds true for the dietary 
low exposure range. This needs to be achieved by monitor-
ing steady-state levels of Hb-adducts and N7-GA-dG DNA 
adducts simultaneously in blood under tightly controlled 
longer term exposure conditions. However, besides the logis-
tic difficulties of maintaining tightly controlled exposure 
conditions for the required extended time periods, the vastly 
different kinetics of the respective blood biomarkers need to 
be taken into consideration in order to establish correlations. 
Therefore simultaneous monitoring of urinary GAMA and 
AAMA as second short term biomarker may be a prerequi-
site. Such studies also need control groups of lowest achiev-
able exposure (verified by duplicate diet) which adds to their 
complexity. The data will be very valuable to substantiate 
the reported findings on endogenous background levels of 
AA exposure which also will most probably be subject to 
individual or health/lifestyle associated variability.
3‑MCPD
Characterization, formation, occurrence and public health 
concern
Monochloropropane-1,2-diols (MCPDs) are contaminants 
that are created during food production, especially in cases 
where foods containing fat and salt are processed at high 
temperatures (Crews et al. 2013). They can be chlorinated in 
the 2- or 3-position (2- and 3-MCPD, respectively). 3-MCPD 
was originally identified at high levels in acid hydrolysed 
vegetable proteins and soy sauce, but can be found in many 
food types (European Commission 2004). Analytical data on 
2-MCPD occurrence are scarcer. 2-MCPD may occur in pro-
cessed vegetable oils and foods that use processed vegetable 
oils as ingredients (Tennant and Gosling 2015), 3-MCPD 
is primarily found as fatty acid esters in a mixture of both, 
mono- and di-esters (MacMahon et al. 2013). The current 
understanding, based on the results from a limited number 
of 3-MCPD esters, is that enzymatic hydrolysis of the esters 
occurs at a significant rate in vivo, resulting in close correla-
tions between the potency of free versus esterified 3-MCPD 
(Abraham et al. 2013). In the current risk assessment it is 
considered that both bound (in fatty acid esters) and free 
3-MCPD are to be grouped as sources of 3-MCPD exposure. 
In animal studies, 3-MCPD is toxic to the kidney and testes 
and a TDI was previously established by JECFA at 4 µg/
kg bw/day using the benchmark dose modelling approach 
(JECFA 2016) and EFSA is currently revising their TDI 
(EFSA 2017a).
Urinary biomarkers
Two studies in rats, with different methodological 
approaches, have conducted urinary analysis of 3-MCPD, 
3-MCPD dipalmitate, and their metabolites. In one study 
(Barocelli et  al. 2011), urine was analysed for several 
metabolites (such as the mercapturic acid and glucuro-
nide metabolites), while the other study (Abraham et al. 
2013) measured in urine parent 3-MCPD and 3-MCPD 
dipalmitate. In both studies, a small percentage (< 5%) of 
the administered 3-MCPD or 3-MCPD dipalmitate was 
recovered unmetabolized in the urine. Furthermore, the 
mercapturate of 3-MCPD, 2,3-dihydroxypropylmercaptu-
ric acid (DHPMA) (Fig. 2) was present at greater con-
centrations than 3-MCPD in urine (Barocelli et al. 2011). 
Glucuronide or sulfo metabolites of 3-MCPD were below 
the limit of detection (Barocelli et al. 2011).
Fig. 2  Biomarkers of 3-MCPD exposure including 2,3-dihydroxypropylmercapturic acid (DHPMA) and possible glucuronide conjugates
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Blood biomarkers
Analysis of blood biomarkers was conducted over 48 h 
after administration of free 3-MCPD or 3-MCPD dipalmi-
tate (Abraham et al. 2013). The total amount of 3-MCPD 
was measured using a method that hydrolysed 3-MCPD 
esters followed by derivatization of all free 3-MCPD. 
The researchers concluded that overall bioavailability 
of 3-MCPD and 3-MCPD dipalmitate were similar, with 
the dipalmitate having 86% of the bioavailability of free 
3-MCPD. However, the data also demonstrated that the 
kinetics of the dipalmitate were delayed relative to free 
3-MCPD, with Tmax being reached at 3 h and 22 min, 
respectively. At the same time, the maximum blood con-
centration Cmax was 5 times higher for dipalmitate ver-
sus free 3-MCPD (0.95 versus 4.85 µg/mL, respectively) 
(Abraham et al. 2013).
Tissue biomarkers
The same study has shown that metabolites of 3-MCPD 
exposure can be detected in a number of tissues within 24 h 
after oral exposure: liver, kidney, fat, and intestine (Abraham 
et al. 2013). As with the analysis in blood, total 3-MCPD 
in the tissues was measured, accounting for both free and 
esterified 3-MCPD present. As with circulating metabolites, 
the total amount of 3-MCPD found in tissues over the first 
24 h was similar when free and 3-MCPD dipalmitate were 
administered orally, but maximum concentrations in the 
tissues occurred earlier with the free form. This supports 
the observation with circulating biomarkers of 3-MCPD for 
more rapid kinetics of the free versus esterified form.
Available PBK studies
As described in the previous sections, there have been lim-
ited studies conducted analysing the bioavailability and tis-
sue distribution of 3-MCPD after oral exposure. However, 
so far these data have not been used to develop a pharma-
cokinetic model for oral exposure to 3-MCPD or its esters.
Endogenous formation and accompanying levels 
of the biomarkers
No sources of endogenous 3-MCPD have been identified, 
however, some of the urinary metabolites of 3-MCPD, such 
as the mercapturic acid, are known to be shared with other 
compounds, such as epichlorohydrin (De Rooij et al. 1997) 
and glycidol (Eckert et al. 2011). Analytical methods have 
been developed for 2,3-dihydroxypropyl mercapturic acid 
(DHPMA), which is a common metabolite of 2-MCPD, 
3-MCPD, glycidol and epichlorohydrin, but these methods 
are unable to differentiate from which parent compound 
DHMPA is formed (Eckert et al. 2010). Contribution from 
chemicals like epichlorohydrin to urinary metabolites com-
mon to 3-MCPD are unlikely to be significant, except in 
cases of extreme exposure (De Rooij et al. 1996, 1997), and 
therefore would only infrequently lead to complication in 
interpretation of urinary biomarker data. However, using a 
urinary metabolite like DHPMA as a biomarker for 3-MCPD 
could be complicated by the presence of co-occurring gly-
cidyl esters (Crews et al. 2013). The hypothesis that urinary 
DHPMA reflect also a hitherto unknown endogenous C3 
metabolite, as previously reported by Eckert et al. (2011), 
is strongly underpinned by a recent study (Hielscher et al. 
2016). In this study, a male volunteer, who avoided intake 
of food containing refined fats for 2 days, ingested a com-
paratively high amount of a commercial frying fat with 
defined levels of 3-MCPD and glycidol fatty acid esters 3 
times every 2 days. In parallel DHPMA was determined as 
urinary biomarker. After oral administration of the frying 
fat, the average DHMP level remained relatively constant 
and a clear increase in urinary DHPMA excretion could not 
be detected. It was concluded that oral exposure to foods 
with realistic background levels of glycidol or 3-MCPD fatty 
acid esters is not able to increase the urinary excretion of 
DHPMA. This study clearly indicates the significance of 
the formation of this biomarker from another endogenous 
or exogenous source.
Data gaps and research needs
In light of studies that successfully detected 3-MCPD or 
other markers of 3-MCPD in biological samples (Barocelli 
et al. 2011; Abraham et al. 2013), significant challenges 
remain for validating these measurements as biomarkers of 
dietary exposure to 3-MCPD and its esters. These challenges 
can be summarized as either technological or biological, but 
all of these factors contribute to the fact that there are not 
sufficient data to establish a correlation between the amount 
of 3-MCPD consumed and any of these biomarkers.
It needs to be determined whether the characterization 
of the 3-MCPD esters is required, or whether measurement 
of total 3-MCPD provides enough information to create a 
correlation. If direct measurement of the esters is necessary 
to account for the different bioavailability of the esters, then 
method development would be needed to assess for all esters 
in blood. This may also require development of broadly 
available analytical standards for the esters. If urinary analy-
sis is pursued, there would be the need for additional analyti-
cal standards for many of the urinary metabolites, such as 
the glucuronide- and sulfo-conjugates (Barocelli et al. 2011).
Biologically, validation of biomarkers for exposure needs 
to account for the complexity of differences in bioavailabil-
ity between both free and esterified 3-MCPD, as well as 
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between the different 3-MCPD esters. Currently, only the 
dipalmitate has been evaluated (Abraham et al. 2013). As 
evidenced by these data, there were differences between bio-
availability of the free and esterified forms. However, due 
to the rapid hydrolysis of esters in the body (Abraham et al. 
2013; EFSA 2016), development of biomarkers for the dif-
ferent 3-MCPD esters is likely unnecessary.
Glycidyl esters
Characterization, formation, occurrence and public health 
concern
2,3-Epoxy-1-propanol (glycidol) esters were originally used 
as raw materials and stabilizers to produce polymers in the 
cosmetic and pharmaceutical industries. In 2009, the Ger-
man Federal Institute for Risk Assessment (BfR) detected 
glycidyl fatty acid esters (GEs) in refined vegetable fats 
and expressed concern over the possible release of the sus-
pected human carcinogen glycidol during gastrointestinal 
digestion (BfR 2009a, b; Bakhiya et al. 2011). Subsequently, 
GEs were discovered in refined edible oils and fats or foods 
containing them (Masukawa et al. 2010; Weißhaar and Perz 
2010; Blumhorst et al. 2011, 2013; Kuhlmann 2011; Craft 
et al. 2013; Crews et al. 2013; MacMahon et al. 2013; Wöhr-
lin et al. 2015). Studies indicate that heat treatment gener-
ates GEs and, particularly, the deodorization process in oil 
refining (Franke et al. 2009; Matthäus et al. 2011). Recently, 
Inagaki et al. (2016) demonstrated high concentrations of 
GEs in meat samples heated at high temperatures. The com-
position of the heat-formed GEs agreed with the fatty acid 
composition of non-heated samples, indicating that the fatty 
acids and triglycerides in foods could be converted to GEs.
Carcinogenicity evaluations reported that subcutaneous 
injection of glycidyl oleate or stearate in mice resulted in low 
or insignificant increases in local tumour incidences (Wal-
pole 1958; Swern et al. 1970; Van Duuren et al. 1972). Thus, 
the IARC classified glycidyl oleate and stearate as “Not clas-
sifiable as to its carcinogenicity to humans” (IARC 1976, 
1987). Genotoxicity studies of glycidyl linoleate, including 
the Ames test in five strains, chromosome aberration test in 
Chinese hamster lung cells, and micronucleus formation in 
mice, suggested that glycidyl linoleate is to be considered 
non-genotoxic, since a positive result in the Ames test of 
glycidyl linoleate was attributed to the release of glycidol 
(Ikeda et al. 2012). Glycidol has shown mutagenic effects 
in vitro in bacterial tests with and without metabolic activa-
tion, and a wide spectrum of genotoxic effects in mammalian 
cell systems (genetic mutations, chromosomal aberrations, 
sister chromatid exchanges, unscheduled DNA synthesis). 
In vivo genotoxicity tests were less conclusive, some posi-
tive results were reported in micronucleus assays in mice 
after intraperitoneal administration, but not in others (IARC 
2000; EFSA 2016). The toxicological and carcinogenic 
potential of glycidol has sufficiently been investigated by 
NTP and IARC (NTP 1990; IARC 2000). Following evi-
dence of carcinogenicity in mice and rats, the IARC evalu-
ated glycidol as “probably carcinogenic to humans” (Group 
2A), although no epidemiological data were available.
Urinary biomarkers
2,3-Dihydroxypropyl mercapturic acid (DHPMA), previ-
ously discussed in regard to 3-MCPD (Sect. 2.2.2), is also a 
urinary biomarker of glycidol and its esters (Fig. 3). In addi-
tion to the studies of DHMPA described above (Eckert et al. 
2011), Appel et al. (2013) also measured DHPMA to inves-
tigate the oral bioavailability of glycidol from GEs in rats. 
Rats were administered glycidyl palmitate or an equimolar 
dose of glycidol and urine was collected at 0–8, 8–24, and 
Fig. 3  Biomarkers of glycidol/glycidylester exposure including 2,3-dihydroxypropylmercapturic acid (DHPMA) and N-(2,3-dihydroxypropyl)
valine (diOHPrVal) and several DNA adducts
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24–48 h after dosing. The urinary DHPMA level reached the 
highest concentration at 0–8 h, and almost all the DHPMA 
was excreted at 8–24 h in both treatment groups. No signifi-
cant differences occurred between the glycidol and glycidyl 
palmitate groups.
Blood biomarkers
Glycidyl-haemoglobin adducts have been used to assess 
GEs because GEs are mainly absorbed as glycidol (Waka-
bayashi et al. 2012; Appel et al. 2013). Landin et al. (1996) 
demonstrated the covalent binding of glycidol to N-terminal 
valine of haemoglobin in vitro. Furthermore, the N-(2,3-
dihydroxypropyl)valine (diHOPrVal) adduct (Fig. 3) was 
detected using the N-alkyl Edman GC-MS/MS method 
(Landin et  al. 1996), initially established to investigate 
external and/or internal exposure to epichlorohydrin. Back-
ground levels of diHOPrVal were detected in control sub-
jects (Landin et al. 1996, 1997). More recently, Aasa et al. 
(2017) developed a more convenient analytical method to 
evaluate diHOPrVal using LC-MS/MS and the new derivat-
izing reagent, fluorescein isothiocyanate, as an alternative to 
earlier GC-MS/MS methods. They confirmed correlations 
among administered dose of glycidol, diHOPrVal levels, and 
micronuclei frequencies in experiments on mice. Further-
more, Hielscher et al. (2017) reported a similar method using 
fluorescein isothiocyanate and UPLC-MS/MS technique. 
Glycidol forms dihydroxypropyl adducts in biomolecules. 
Related substances in foodstuffs (including anhydrosugars, 
allyl alcohol, and glycerol halohydrins), have been discussed 
as possible precursors of glycidol (Hauschild and Petit 1956; 
Jones 1975; Patel et al. 1980; Piasecki et al. 1990; Hamlet 
1998; Ishidao et al. 2002) that might account for background 
diHOPrVal. Furthermore, subsequent studies revealed that 
diHOPrVal levels in tobacco smokers are higher than those 
in non-smokers (Landin et al. 1996), and levels in rats fed a 
fried diet were higher than those in control rats (Landin et al. 
2000). Moreover, Honda et al. (2011, 2012) used diHOPrVal 
for exposure evaluation in humans who ingested diacylglyc-
erol (DAG) oil containing high levels of GEs compared to 
other edible oils (Masukawa et al. 2010). The diHOPrVal 
was detected in all subjects regardless of DAG exposure 
level, and did not differ between DAG- and non-exposed 
subjects. GE-induced internal exposure to glycidol was 
possibly not markedly higher than that induced by other 
unknown sources of internal exposure, which could con-
tribute to background diHOPrVal levels.
Furthermore, diHOPrVal formation by glycidol expo-
sure had only been demonstrated in  vitro and had not 
been characterized as an in vivo exposure marker of gly-
cidol and GEs until the early 2000s, whereas the diHOPr-
Val formed by epichlorohydrin exposure in rats had been 
(Landin et al. 1999). Following this situation, Appel et al. 
(2013) demonstrated diHOPrVal formation in rats after oral 
administration of glycidol and glycidyl palmitate. Formation 
was slightly delayed in the glycidyl palmitate group while 
total levels were comparable in both groups, indicating that 
glycidyl palmitate was entirely hydrolyzed to glycidol and 
palmitic acid. Moreover, Honda et al. (2014) confirmed the 
dose-dependent formation, chemical stability in vivo, and 
sensitivity of diHOPrVal measurements in kinetics studies 
in rats orally administered glycidol. Moreover, in vivo doses 
calculated from the second-order reaction rate constant 
in vitro agreed with the area under the concentration–time 
curve (AUC) values determined in rat short-term toxicoki-
netic studies (Wakabayashi et al. 2012). Therefore, diHOPr-
Val is considered useful for estimating AUC values, at least 
following controlled short-term oral exposure. DiHOPrVal 
is also of use to estimate daily exposure levels from accu-
mulated or steady-state levels using mathematical models 
(Fennell et al. 1992; Granath et al. 1992) because diHOPrVal 
would be stable in vivo over the lifetime of the erythrocyte 
(Honda et al. 2014).
Tissue biomarkers
In vitro studies demonstrated that glycidol reacts with DNA 
bases and, therefore, glycidyl-DNA adducts could be tissue 
biomarkers of glycidol-related compounds including GEs, 
which release glycidol during gastrointestinal digestion. 
Hemminki et al. (1980) reported that glycidol reacted with 
deoxyguanosine to produce 1,7-(or 1,9)-dialkylguanine, with 
deoxyadenosine to produce adducts at N6, with deoxycyti-
dine at N3 by incubating with each deoxyribonucleoside. 
Subsequently, Segal et al. (1990) identified a thymidine 
and uridine adduct at N3 formed by the in vitro reaction 
of glycidol and calf thymus DNA. They also demonstrated 
that N3 uridine adducts were rapidly formed by hydrolytic 
deamination of N3 cytosine adducts. Moreover, Solomon 
(1998) reported that several epoxides including glycidol 
formed adducts with deoxyguanosine at N7 and with deoxy-
adenosine at N3 as major adducts. Toshima et al. (2003) 
also reported that glycidol selectively alkylated DNA at the 
N7 sites of the guanines. Furthermore, Ozcagli et al. (2016) 
reported high purine base damage, indicating N7 guanine 
alkylation in glycidol-induced HEK-293 cells. The N7 of 
guanine is the major site of alkylation by epoxides that may 
lead eventually to point mutations by depurination (Mel-
nick 2002). The glycidol-DNA adduct formation in vivo has 
not been investigated. However, these findings indicate that 
DNA adducts may be formed by exposure to glycidol in vitro 
and in vivo, and could be a biomarker of biologically effec-
tive doses of glycidol released from GEs in target tissues 
and organs.
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Available PBK studies
No PBK model for GEs has been developed to date. In 
related studies, Frank et al. (2013) investigated the fate of 
GEs including their biotransformation into glycidol. Static 
and dynamic gastrointestinal models were used to determine 
lipase and pH effects on different GEs. Although GEs are 
stable at pH 1.7–4.8, they are rapidly hydrolysed follow-
ing the addition of lipase. Under the conditions of dynamic 
simulation and in food matrix models, the transformation to 
glycerol was very small. Transformation to MCPD occurred 
only after extended incubation time and at very small quan-
tities. These results agreed with those of rat toxicokinetic 
and bioavailability studies (Wakabayashi et al. 2012; Appel 
et al. 2013). In contrast, Onami et al. (2015) pointed out 
that glycidol or GEs might be converted to 3-MCPD in the 
rat gastrointestinal tract based on their in vivo experiments 
(single oral gavage, 1 time point) and ex vivo experiments 
(incubation with gut content samples). These studies did not 
derive PBK parameter values directly. However, toxicoki-
netic information reported in these studies might be useful 
for constructing PBK models.
Endogenous formation and accompanying levels 
of available biomarkers
Eckert et al. (2011) reported relatively high background 
DHPMA levels in human urine, which strongly correlated 
with urinary creatinine (r = 0.945, p < 0.0001, regression 
analysis). Similarly, Andreoli et al. (2015) reported a weak 
correlation between DHPMA and creatinine in human urine 
(r = 0.176, p < 0.022, in Spearman’s correlation); however, 
the correlation was not as high as that observed by Eckert 
et al. (2011). Whether the difference between both studies 
is only attributable to the difference in analytical methods 
is unknown. Moreover, the smoking status of the human 
subjects, which might affect the external exposure to gly-
cidol, was not correlated with urinary DHPMA concentra-
tions (Eckert et al. 2011; Andreoli et al. 2015). Thus, these 
findings raised the hypothesis that an endogenous bioprocess 
could generate DHPMA. The correlation of DHPMA levels 
with 3-hydroxypropyl mercapturic acid (3-HPMA), an acr-
olein biomarker, indicates an identical C3 precursor.
Data gaps and research needs
Extending the applicability of DHPMA to GE exposure eval-
uation will require establishment of dose-dependency and 
highly sensitive analytical methodology because GE food 
levels are normally rather low. Furthermore, DHPMA is not 
specific to glycidol because it is derivable from glycidol and 
3-MCPD (Jones 1975). The relationship between glycidol 
exposure and DHPMA levels has not been confirmed in 
humans. Therefore, the combination analysis of DHPMA 
and haemoglobin adducts, which are not considered 
3-MCPD biomarkers may lead to more precise GE expo-
sure evaluation in humans, covering short- and long-term 
exposures.
Haemoglobin adducts, including diHOPrVal, cannot be 
used as tissue biomarkers for assessing target organ or tissue 
exposure levels. Therefore, for cancer risk assessment, tissue 
biomarkers such as DNA adducts are considered superior to 
haemoglobin adducts in target tissues. However, contrary 
to mercapturic acids, haemoglobin adducts would be more 
suitable as chronic exposure biomarkers. Further studies on 
background levels of diHOPrVal in humans and animals and 
the use of other protein adducts as biomarkers are required.
No in vivo studies are available on glycidol-DNA adduct 
formation. Therefore, the value of glycidyl-DNA adducts to 
determine exposure in humans who ingest foods containing 
small amounts of GEs needs clarification. The elucidation of 
DNA adduct types formed and their levels in animal experi-
ments would be required. Clearly, large-scale sampling of 
tissue DNA adducts is difficult and would only be applicable 
in limited studies/population groups.
Furan
Characterization, formation, occurrence and public health 
concern
Furan is a highly volatile, oxygen containing heterocyclic 
compound that was found to be formed unintentionally in 
heat processed foods, particularly in coffee and in canned 
and jarred foods. Multiple precursors have been identified 
that are natural food components, including carbohydrates, 
amino acids, polyunsaturated fatty acids and carotenoids. 
Different precursors and formation pathways have been dis-
cussed for dry heating (e.g. coffee roasting) or wet heating 
(retort sterilization) (Mariotti et al. 2013). Retort processing 
prevents furan from evaporating, and during coffee roasting 
the furan formed remains ‘trapped’ inside the roasted bean 
and even in roast and ground coffee. Once ‘bound’ in the 
matrix furan does not easily evaporate, for example upon 
re-heating of jarred foods prior to consumption (Goldmann 
et al. 2005; Roberts et al. 2008; Kim et al. 2009) or after 
brewing of coffee where a considerable amount may remain 
in the brew (Goldmann et al. 2005; Guenther et al. 2010). 
The final concentrations of furan depend on multiple factors 
such as industrial or home processing, preparation for con-
sumption (type of brewing, microwave or stove heating) and 
individual consumption habits as, e.g. stirring. Thus analyti-
cal data generated on products as taken from the shelf do not 
reflect the amounts ingested by the consumer. Furthermore, 
reliable quantitative information on evaporation losses are 
unavailable and difficult to estimate or generalize. Although 
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furan can be found in the environment (combustion, cigarette 
smoke, etc.), main human exposure was identified to occur 
via food (JECFA 2011). In rodent studies, furan is toxic to 
the liver and a carcinogen (NTP 1993; JECFA 2011; Von 
Tungeln et al. 2017). There is sufficient evidence that toxic-
ity is induced by cytochrome P450 (CYP 2E1) mediated 
bioactivation to a reactive metabolite, cis-2-butene-1,4-dial 
(BDA) (Fig. 4) that is able to covalently bind to macromol-
ecules such as proteins and DNA. There is some controversy 
about the genotoxicity of furan due to inconclusive results 
of in vivo and in vitro genotoxicity tests. Some scientists 
argue for a non-genotoxic mechanism of action secondary to 
cytotoxicity exerted in the liver (Ding et al. 2012; McDan-
iel et al. 2012; Terrell et al. 2014; Churchwell et al. 2015), 
which is also supported by gene expression studies (Chen 
et al. 2010, 2012; Dong et al. 2016, Tryndvak et al. 2017). 
However, JECFA concluded that in the carcinogenicity of 
furan a genotoxic mechanism of action cannot be excluded 
and a non-threshold effect was assumed. Application of the 
Margin of Exposure (MOE) approach indicated a potential 
human health concern and it was recommended to explore 
possible measures that could reduce consumer exposure 
(JECFA 2011). In a recent evaluation of the risks for public 
health related to the presence of furan in food, the EFSA 
Panel on Contaminants in the Food Chain concluded that 
there was limited evidence for a direct genotoxic mecha-
nism in furan carcinogenicity, whereas there was clear evi-
dence for an involvement of indirect mechanisms, including 
epigenetic changes, inflammation, oxidative DNA damage 
and regenerative cell proliferation subsequent to liver injury 
(EFSA 2017b). The Panel also noted that the contribution 
of these factors to furan carcinogenicity may well vary with 
dose, duration of exposure and severity of tissue damage 
(EFSA 2017b). However, considering the uncertainties 
regarding involvement of direct genotoxic mechanisms in 
furan carcinogenicity, the Panel decided that a tolerable 
daily intake (TDI) could not be established and applied the 
MOE approach to the risk characterization using both non-
neoplastic and neoplastic effects. The Panel concluded that 
the calculated MOEs, which were below 100 for non-neo-
plastic effects and smaller than 10,000 for neoplastic effects, 
indicate a health concern (EFSA 2017b).
More recently, occurrence and toxicological information 
have become available on alkylated furans, particularly 2- 
and 3-methylfuran, and 2,5-dimethylfuran that provide some 
evidence for similar (or overlapping) formation pathways 
Fig. 4  Metabolic pathways of furan leading to formation of potential 
biomarkers of furan exposure. Metabolites identified as possible bio-
markers of exposure in rat urine include: NAcLys-BDA (1), which 
results from the reaction of BDA with lysine and subsequent N-acety-
lation; a mono GSH-BDA conjugate (2), which results from conjuga-
tion with GSH and intermolecular reaction with the α-amino group of 
the GSH glutamyl residue; metabolites in which GSH is crosslinked 
by BDA with glutamic acid (3) or lysine (4); NAcCys-BDA-NAcLys 
(6) and its sulfoxide (7), which represent N-acetylated crosslinks of 
cysteine and lysine by BDA. In humans, NAcCys-BDA-Lys sulfoxide 
(5) was identified as a potential urinary biomarker of human exposure 
to furan. Metabolites in which cysteine and lysine are cross-linked by 
BDA may result from either degradation of protein adducts or enzy-
matic processing of the GSH-BDA-Lys conjugate (4). Note that con-
jugation of BDA with GSH can also occur at the 2-position instead 
of the 3-position of the pyrrole ring. For reasons of clarity, only the 
3-substituted metabolites are shown
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and co-occurrence, though occurrence does not always seem 
to be correlated (e.g. Becalski et al. 2010; Chaichi et al. 
2015). Occurrence, absorption, distribution, metabolism, 
and excretion (ADME) and toxicological information is 
still limited on these compounds and they are not addressed 
in this study. In its recent assessment, the European Food 
Safety Authority Panel on Contaminants in the Food Chain 
considered that a full assessment of methylfurans is pres-
ently not possible due to a lack of toxicity and occurrence 
data. Nevertheless, it was considered adequate to group these 
compounds and dose additivity was assumed (EFSA 2017a).
Urinary biomarkers
The ADME characteristics of furan after oral intake in ani-
mal studies were extensively reviewed by JECFA (2011). 
Important routes of furan elimination are expired air  (CO2 
and other volatiles), urine and faeces, accounting for elimi-
nation of 40, 20 and 22% of the administered dose, respec-
tively, 24 h after a single dose of 8 mg/kg bw (Burka et al. 
1991). A number of metabolites of furan were isolated from 
the urine after oral administration of radiolabelled furan to 
rats (Burka et al. 1991). They were suspected to be glu-
tathione (GSH) and mercapturic acid conjugates derived 
from the reactive dialdehyde intermediate of furan, cis-2-
butene-1,4-dial (BDA), generated by CYP2E1 activity in 
the liver (Fig. 4), but the structures were initially not identi-
fied (Burka et al. 1991). The identity of urinary metabolites 
was more recently studied in furan treated rats. Of several 
conjugates derived from the reaction of furan with GSH 
(as identified after reaction of BDA (e.g. after hydrolysis 
of the BDA precursor 2,5-diacetoxy-2,5-dihydrofuran) with 
GSH in vitro or in microsomal extracts), only the mono-
glutathione conjugate (GSH-BDA) (2) (Fig. 4) was identi-
fied in rat urine after oral dosing (Peterson 2006; Kellert 
et al. 2008). This GSH-BDA adduct was proposed to be a 
promising urinary biomarker. Additional metabolites gen-
erated from the reaction of BDA or GSH-BDA with free 
or protein-bound lysine as well as BDA-derived cysteine-
lysine crosslinks were identified in rat urine after oral furan 
treatment in vivo (Lu et al. 2009). These include R-2-acet-
ylamino-6-(2,5-dihydro-2-oxo-1H-pyrrol-1-yl)-1-hexanoic 
acid, which results from the reaction of BDA with lysine 
and subsequent N-acetylation (NAcLys-BDA) (1) (Fig. 4), 
as well as N-acetyl-S-[1-(5-acetylamino-5-carboxypentyl)-
1H-pyrrol-3-yl]-l-cysteine (NAcCys-BDA-NAcLys) (6) 
and its sulfoxide (7) (Fig. 4), which represent N-acetylated 
crosslinks of cysteine and lysine by BDA (Lu et al. 2009). 
In a mass spectrometric analysis of urine from furan treated 
rats, combined with multivariate analysis for metabolic pro-
filing, a number of metabolites were identified as possible 
furan biomarkers of exposure. These were characterized 
as lysine- (1), mercapturate- (6) or mercapturate sulfoxide 
(7) conjugates, a GSH and a glutamic acid adduct (3), all 
derived from the BDA metabolite and containing a pyrrole 
ring structure derived from the ring closure of the BDA mol-
ecule (Kellert et al. 2008) (Fig. 4), and overlapping with the 
ones identified by Peterson and Lu above. No examples of 
application of these biomarkers to correlate dietary furan 
exposure in animals or humans are available yet. However, 
one study addressed the presence of urinary furan exposure 
biomarkers in three cohorts of smokers versus non-smokers 
comprising between 5 and 15 subjects per group (Grill et al. 
2015). Metabolites derived from direct interaction of BDA 
with lysine and from crosslinks of cysteine-BDA-lysine 
(Fig. 4) were analysed but not all metabolites were consist-
ently identified and quantified due to interfering peaks or 
high variability of the results in the LC-MS/MS analysis. 
While the NAcCys-BDA-NAcLys (6) and its sulfoxide (7), 
consistently reported to occur in rat urine, were below the 
limit of detection in humans pointing at a possible inter-
species difference, one of the N-acetylcysteine-BDA-lysine 
metabolites, the NAcCys-BDA-Lys sulfoxide metabolite (5) 
(Fig. 4), was strongly correlated with smoking in all three 
cohort studies from the US, Shanghai, and Singapore. Its 
levels were more than 10 times higher in urine from smokers 
than in urine from non-smokers, and levels decreased imme-
diately upon cessation of smoking. The NAcCys-BDA-Lys 
sulfoxide (5) was postulated to be a degradation product of 
adducted proteins, and as such a promising marker for furan 
metabolism to BDA and also a potential biomarker of furan 
toxicity (furan induced protein damage) (Grill et al. 2015). 
Besides degradation of protein adducts, enzymatic process-
ing of the GSH-BDA-Lys conjugate (4) (Fig. 4) may also 
lead to the formation of metabolites in which cysteine and 
lysine are cross-linked by BDA.
Blood biomarkers
Twenty-four hours after oral administration of radioactively 
labelled furan to rats, less than 1% (0.42%) of the dose was 
present in blood (Burka et al. 1991). While radioactivity 
was eliminated quickly from liver, elimination from kidney 
and blood was more slowly, with levels in blood remaining 
rather constant for 8 days following a single dose treatment, 
indicating some covalent binding to macromolecules. The 
level of binding increased with repeated application com-
pared to single dosing over 8 days. In a recent toxicokinetic 
study in rats with single oral furan administration at a dose 
of 0.92 mg/kg bw/day, furan levels in blood decreased rap-
idly with a half-life of 1.3 h and were undetectable 8 h after 
dosing (Churchwell et al. 2015). No blood-specific mac-
romolecular adducts with furan were characterized and no 
studies related to blood exposure markers were found in the 
published literature.
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Tissue biomarkers
Studies on the identification of tissue macromolecular 
adducts have focused on the liver, since it is the organ of bio-
activation to BDA, and the organ with the highest furan con-
centration in rodent ADME studies with oral administration 
of radioactively labelled furan. Due to the non-extractability 
of furan-associated radioactivity, it was suggested that furan 
was bound to proteins in rat liver. With repeated dosing at 
daily doses of 8 mg/kg for 8 days, furan levels increased 
almost linearly up to day 4, reaching a plateau between 4 
and 8 days of dosing. No DNA binding was initially identi-
fied in rat liver in vivo (Burka et al. 1991), whereas DNA 
adducts with deoxyadenosine, deoxycytidine and deoxy-
guanosine were identified after reaction of BDA with calf 
thymus DNA or DNA isolated from S. typhimurium strain 
TA104 after treatment with mutagenic concentrations of 
BDA (Byrns et al. 2006). In a more recent study employing 
accelerator mass spectrometry (AMS), a significant, dose-
related increase in 14C-content in rat liver DNA (correspond-
ing to 1.7 ± 0.7 and 32.5 ± 21.2 adducts/108 nucleotides at 
0.1 and 2.0 mg/kg bw, respectively) was observed after oral 
administration of [3,4-14C]-furan (0.1 and 2.0 mg/kg bw) 
to F344 rats. However, DNA adducts with deoxyadenosine, 
deoxycytidine and deoxyguanosine identified after reac-
tion of BDA with DNA in vitro were not detected in rat 
liver using LC-MS/MS, even after treatment with a single 
high dose (30 mg/kg bw) of furan or after repeated admin-
istration of lower doses (2 mg/kg bw/day) for 28 days, with 
LODs of 3.3–6.6 adducts/108 nucleotides (Neuwirth et al. 
2012). Although radioactivity was significantly and cova-
lently bound to DNA and metabolic incorporation of 14C 
was excluded, attempts to characterize the DNA modifica-
tions carrying the radiolabel failed (Neuwirth et al. 2012). It 
was suggested that the primary DNA adducts may rearrange 
further, possibly also forming crosslinks that are structur-
ally difficult to assess. The formation of crosslinks has been 
proposed indirectly based on results from a Comet assay in 
CHO cells and turkey foetal liver cells (Marinari et al. 1984; 
Jeffrey et al. 2012), but no chemical structural characteriza-
tion was provided.
In line with the study by Neuwirth et al. (2012), no evi-
dence for DNA adduct formation (BDA-2′-deoxycytidine) 
in rat liver was found by Churchwell et al. (2015) using 
LC-MS/MS after dosing for up to 360 days at a dose of 
9.2 mg/kg bw/day.
While several proteins were recently identified as targets 
for covalent modification by furan reactive metabolites, 
chemical characterization of the adducted proteins is still 
lacking (Moro et al. 2012). Recently, Nunes et al. (2016) 
reported formation of a cross-link between GSH-BDA and 
lysine 107 of histone H2B in livers of male F344 rats treated 
with furan. This modification was detected in vivo after 
treatment with furan (0.92 mg/kg bw) and was observed 
prior to the occurrence of epigenetic histone alterations, 
leading the authors to conclude that covalent histone modi-
fication by reactive furan metabolites may be linked to ini-
tial stages of tumour development by furan. In addition to 
providing mechanistic insight into furan carcinogenicity, the 
identified cross-link between GSH-BDA and histone H2B 
may serve as a biomarker of furan exposure.
Available PBK studies
Based on inhalation studies in F344 rats, a physiologi-
cally based pharmacokinetic (PBK) model was developed 
for furan. The model accurately predicted blood and liver 
concentrations of rats exposed to constant furan inhalation, 
which was validated with independent inhalation studies. 
Model simulations of furan metabolism in the rat after a 
single oral dose of 8 mg/kg bw predicted metabolism of 
84% of the dose and 16% exhaled as the parent compound 
(Kedderis et al. 1993), which is in good agreement with 
data reported by Burka et al. (1991) who determined 86% 
of the dose metabolized and 14% of the dose exhaled 24 h 
after a single 8 mg/kg dose. Furan biotransformation kinetic 
parameters determined with freshly isolated rat hepatocytes 
in vitro were found to accurately predict furan pharmacoki-
netics in vivo in rats (Kedderis et al. 1993). Kinetic param-
eters obtained from mouse and human primary hepatocytes 
were furthermore used to build species-specific PBK models 
for furan inhalation exposure that revealed important inter-
species differences with respect to pulmonary absorption, 
steady-state blood concentrations of furan and liver expo-
sure to the metabolite BDA (Kedderis and Held 1996). No 
PBK model studies are available to date on oral (dietary) 
exposure to furan in humans, or on other metabolic reac-
tions apart from oxidation to BDA, such as, e.g. glutathione 
conjugation.
Endogenous formation and accompanying levels 
of the biomarkers
Of several potential biomarkers of furan exposure identified 
by metabolic profiling of rat urine, three metabolites, i.e. 
the NAcLys-BDA adduct (1), the NAcLys-BDA-NAcCys 
(6) as well as an unidentified metabolite, were also found to 
be present in urine of control animals (Kellert et al. 2008). 
Although quantitative analysis was not performed, the ratio 
between these three metabolites in treated versus control 
animals varied considerably. It is unclear if this background 
may be due to low level exposure of control animals to 
furan via rodent diet or endogenous formation unrelated to 
furan exposure (Kellert et al. 2008). There is evidence that 
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chemical oxidation of deoxyribose in DNA gives rise to the 
trans-isomer of 2-butene-1,4-dial (Chen et al. 2004). While 
this may present a plausible pathway for endogenous forma-
tion of BDA adducts, there are at present no data to confirm 
formation of these metabolites in vitro or in vivo. In sum-
mary, endogenous formation cannot be excluded to date, but 
evidence is lacking to back this possibility.
Data gaps and research needs
The application of urinary biomarkers to monitor human 
exposure to furan has not been investigated yet, including the 
use of specific urinary markers as representatives of overall 
furan exposure or specifically for dietary furan exposure. 
Aspects that need further investigations include improved 
analytical methods for sensitive analysis of potential uri-
nary biomarkers of furan exposure (e.g. NAcLys-BDA (1), 
the mono-glutathione conjugate GSH-BDA (2) or the NAc-
Cys-BDA-Lys sulfoxide (5)) at expected low dose dietary 
exposure levels as well as data on the correlation of levels 
of different urinary exposure biomarkers to support a sin-
gle biomarker approach. Besides urinary biomarkers, the 
suitability of haemoglobin adducts as a potential avenue 
to monitor chronic low dose exposure to furan should be 
explored. Furthermore, there is a need to clarify potential 
endogenous formation of furan and 2-butene-1,4-dial, e.g. 
by using duplicate diet methodology. To this end it should 
be emphasized that duplicate diet sampling needs to reflect 
the meal consumption process to take account of the volatil-
ity of furan.
Acrolein
Characterization, formation, occurrence and public health 
concern
Acrolein is the most reactive of α,β-unsaturated aldehydes 
that is formed for instance upon heating of cooking oil, and 
also detected as a constituent of cigarette smoke (lARC 
1993; Kehrer and Biswal 2000; ATSDR 2007; Tang et al. 
2011; Guillén and Uriarte 2012; Moghe et al. 2015). Acr-
olein has also been reported to be a product formed during 
fermentation and ripening processes (Gomes et al. 2002) 
and to be generated endogenously during cellular lipid per-
oxidation and other processes (Uchida et al. 1998; Stevens 
and Maier 2008). In addition, acrolein is well known to be 
formed from several other structurally related xenobiotica 
and as a metabolic by-product from some drugs such as 
the oxazaphosphorine cytostatics (Burcham 2017). Being 
an α,β-unsaturated aldehyde, acrolein reacts with cellular 
nucleophiles including proteins and DNA and forms con-
jugates with glutathione. The reaction with glutathione 
presents an important pathway for its detoxification unless 
glutathione levels are depleted (Ohno et al. 1985; Silva and 
O’Brien 1989; Kehrer and Biswal 2000; Kiwamoto et al. 
2015).
Urinary biomarkers
An important urinary biomarker reflecting exposure to 
acrolein is 3-hydroxypropylmercapturic acid (3-HPMA) 
Fig. 5  Biomarkers of acrolein exposure including 3-hydroxypropylmercapturic acid (3-HPMA), 2-carboxyethylmercapturic acid (CEMA), 
gamma-hydroxy-1,N2-propano-2′-deoxyguanosine (γ-HOPdG) and alpha-hydroxy-1,N2-propano-2′-deoxyguanosine (α-HOPdG)
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(Fig. 5), a major urinary metabolite of acrolein formed from 
the glutathione conjugate of acrolein (ATSDR 2007; Ste-
vens and Maier 2008). Urinary 3-HPMA has been used as a 
biomarker for acrolein exposure in large- and smaller-scale 
biomonitoring studies with healthy non-smoking human vol-
unteers (Carmella et al. 2007; Schettgen et al. 2008; Alwis 
et al. 2015; Hecht et al. 2015; Park et al. 2015). The DFG-
Senate Commission on Food Safety (SKLM) concluded that 
3-HPMA can be used as biomarker of exposure over espe-
cially the last 48 h (Guth et al. 2013). In a pilot study moni-
toring the mercapturic acid content of spot urine samples 
from 14 occupationally non-exposed non-smokers the excre-
tion of 3-HPMA was even found to be at least three times 
that of N-acetyl-S-(2-carbamoylethyl)-l-cysteine (AAMA), 
a biomarker of exposure to acrylamide (Schettgen et al. 
2008). A subsequent study in 13 human volunteers showed 
similar results, since upon consumption of a test meal of 
potato crisps/chips experimentally heat treated to achieve a 
high acrylamide intake (1 mg per person), the excretion of 
3-HPMA was found to be substantially (15-fold) higher than 
that of the acrylamide-related mercapturic acids (Watzek 
et al. 2012a).
Another urinary metabolite of acrolein is 2-carboxyeth-
ylmercapturic acid (CEMA) (N-acetyl-S-2-carboxyethyl-
cysteine) formed via either oxidation of acrolein to acrylic 
acid and subsequent glutathione conjugation or by oxida-
tion of the glutathione conjugate of acrolein, ultimately both 
leading to formation of CEMA (Fig. 5) (Kaye 1973; Linhart 
et al. 1996; Alwis et al. 2015).
When using 3-HPMA as a urinary biomarker for acrolein 
exposure it is of importance to take into account that sev-
eral allylic compounds may also metabolize to 3-HPMA, 
including allylamine, allyl halides, and allyl alcohol and 
ester (ATSDR 2007).
Blood biomarkers
Acrolein reacts with deoxyguanosine to form 1,N2-propano-
deoxyguanosine adducts which were chemically character-
ized after in vitro incubations with calf thymus DNA (Chung 
et al. 1984). The major adducts are thought to be formed 
from Michael-type addition of N2-amine of deoxyguano-
sine (dG) to C3 of acrolein, giving stereoisomeric gamma-
hydroxypropanodeoxyguanosine (γ-HOPdG) (Fig. 5). The 
minor adducts are formed from Michael addition of N1 
of dG to the C3 position, producing stereoisomeric alpha-
hydroxy-1,N2-propano-2′-deoxyguanosine (α-HOPdG) 
(Chung et al. 1984) (Fig. 5).
These two isomers of 1,N2-propanodeoxyguanosine 
adducts have also been detected in studies analysing the leu-
kocyte DNA from healthy non-smokers and smokers (Chen 
2011; Zhang et al. 2011). Acrolein-DNA adducts were also 
detected in blood samples of untreated rats and mice as well 
as in human samples (Nath and Chung 1994; Nath et al. 
1996). Zhang et al. (2011) reported that there was no signifi-
cant difference between the total acrolein-DNA adduct lev-
els in smokers and non-smokers suggesting that glutathione 
conjugation may effectively remove acrolein from external 
exposures such as cigarette smoking, protecting leukocyte 
DNA from damage. These results would imply that levels 
of these DNA adducts may reflect endogenous rather than 
exogenous exposure.
Other biomolecular targets for acrolein that have been 
reported from in vitro studies include amino acid residues, 
cysteine, histidine, and lysine on proteins. Li et al. reported 
on a competitive enzyme-linked immunosorbent assay 
(ELISA) method to detect possible acrolein protein adducts 
in serum of exposed rats (Li et al. 2004).
Tissue biomarkers
Acrolein protein adducts can be assessed using antibody-
based techniques, high-performance liquid chromatography 
(HPLC), and mass spectrometry, and have been demon-
strated in vivo in several tissues (Aldini et al. 2011; Moghe 
et al. 2015).
Acrolein-DNA adducts have also been detected in liver 
and mammary gland samples of untreated rats, mice and 
humans (Nath and Chung 1994; Nath et al. 1996).
Available PBK studies
Kiwamoto et al. (2015) developed physiologically based 
kinetic/dynamic models to examine dose-dependent detoxi-
fication and DNA adduct formation of a group of 18 food-
borne acyclic α,β-unsaturated aldehydes, including acrolein. 
Acrolein was identified to induce the highest DNA adduct 
levels among the 18 aldehydes tested, primarily due to its 
relatively lower detoxification efficiency via oxidation or 
glutathione S-transferase-mediated mediated GSH conjuga-
tion. The PBK model predicted level of formation of acrolein 
GSH conjugates in the liver was only up to 3.3-fold higher 
than the in vivo reported level excreted as mercapturic acids. 
At realistic dietary intake, the PBK model predicted forma-
tion of 0.036 adducts/108 nt for acrolein in the liver which 
is orders of magnitude lower than endogenous background 
levels of structurally similar 1,N2-exocyclic deoxyguanosine 
adducts observed in disease free human liver.
Endogenous formation and accompanying levels 
of the biomarkers
Acrolein can be formed endogenously as a by-product of 
certain metabolic pathways such as lipid metabolism, lipid 
peroxidation, glycolysis, the amino acid turnover or the 
oxidative deamination of polyamines (Uchida et al. 1998; 
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Stevens and Maier 2008; Guth et al. 2013; Burcham 2017). 
For example, acrolein may result from water elimination 
from 2-hydroxypropanal which can be formed via oxida-
tion of the amino acid threonine under oxidative stress or 
enzymatically by myeloperoxidase. Furthermore, the deg-
radation of polyamines such as spermine and spermidine 
by copper-dependent amine oxidases can lead to 3-ami-
nopropanal, which in turn can be converted to acrolein by 
elimination of ammonia (Stevens and Maier 2008; Guth 
et al. 2013). Acrolein can also be produced during amine 
oxidase metabolism of endogenous polyamines (Esterbauer 
et al. 1991; ATSDR 2007; Stevens and Maier 2008; Alwis 
et al. 2015). Another source for endogenous acrolein produc-
tion is from myeloperoxidase metabolism of l-threonine by 
activated human neutrophils (Anderson et al. 1997). Human 
biomonitoring studies which have detected 3-HPMA in urine 
of healthy non-smoking human volunteers provide evidence 
supportive of endogenous production of acrolein (Carmella 
et al. 2007; Hecht et al. 2015). It is at present not clear to 
what extent this endogenous formation contributes to the 
total acrolein exposure, and how to assess exposure from 
exogenous sources against this endogenous background for-
mation (Guth et al. 2013).
Data gaps and research needs
For use of any of the above biomarkers in acrolein expo-
sure assessment definition of correlations between external 
exposure and levels of the respective biomarkers remain to 
be established preferably for the human situation. Such cor-
relations will need to take the contribution form endogenous 
formation of acrolein into account, including factors causing 
inter-individual differences in both endogenous formation as 
well as in formation of the various biomarkers at a certain 
level of exposure. At present it is not clear to what extent 
this endogenous acrolein formation contributes to the total 
acrolein exposure, and how to assess the external exposure 
against this endogenous formation. Urinary 3-HPMA has 
been used as biomarker for acrolein exposure especially in 
a qualitative way and its further use to define quantitative 
acrolein exposure levels is currently hampered by the fact 
that also other compounds may metabolize to 3-HPMA, 
which may complicate the definition of quantitative relation-
ships. Levels of DNA adducts in leukocytes may also reflect 
exposure to acrolein but also for this biomarker the relative 
contribution from endogenous sources of acrolein needs to 
be better understood and quantified. This also holds for the 
various possible tissue biomarkers consisting of amino acid 
or protein adducts or tissue DNA adducts.
Discussion and conclusions
From the overview presented above it becomes clear that 
the field of complementary approaches to exposure assess-
ment of process-related contaminants in food by biomarker 
monitoring is promising and still under development. The 
next sections discuss the challenges and future perspectives 
defined.
Use of biomarkers in exposure assessment 
for process‑related contaminants
Formation of process-related contaminants including acryla-
mide, 3-MCPD esters, glycidyl esters, furan and acrolein is 
well established although some data gaps exist in the identi-
fication of the variety of pathways and reactions contributing 
to their formation in food upon processing. Their intrinsic 
reactivity and sometimes volatility implies that analytical 
data generated on products as taken from the shelf do not 
reflect the amounts ingested by the consumer, and reliable 
quantitative information on evaporation losses are unavail-
able and difficult to estimate or generalize.
Deriving accurate consumer exposure estimates for 
process-related contaminants from food occurrence and 
consumption data is thus complicated. Use of biomarkers 
may provide a novel approach to exposure assessment of 
process-related contaminants in food. At the current state 
of the art various urinary, blood and/or tissue biomarkers 
are available that may reflect exposure to process-related 
contaminants. These biomarkers have already been used to 
monitor human exposure levels, generally in a qualitative 
way. Use of biomarker data to inform quantitative exposure 
assessment may require definition of correlations between 
quantitative biomarker data and external exposure levels. For 
use of any of the above biomarkers in exposure assessment 
definition of correlations between external exposure and 
levels of the respective biomarkers remain to be established 
preferably for the human situation.
Defining correlations between external exposure 
and biomarker levels
A parameter reflecting a relationship between levels of exter-
nal exposure and a biomarker levels is the so-called bio-
monitoring equivalent (BE), defined as the concentration or 
range of a chemical or its metabolites in a biological medium 
(blood, urine, or specific tissue) that reflect exposure below 
existing health-based exposure guidance value such as a Ref-
erence Dose (RfD) or Tolerable or Acceptable Daily Intake 
(TDI or ADI) (Hays and Aylward 2008).
For several compounds, including the process-related 
contaminants acrylamide and furan, such BE values have 
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been defined (Hays and Aylward 2008, 2009). For acryla-
mide BEs are calculated especially for the AA haemoglo-
bin valine terminal adduct [N-(2 carbamoylethyl)valine 
(AA-Val)], the GA-haemoglobin valine terminal adduct 
[N-(2-carbamoyl-2-hydroxyethyl)valine (GA-Val)], and the 
urinary AA mercapturic acid N-acetyl-S-(2-carbamoylethyl)
cysteine (AAMA) (Hays and Aylward 2009).
Another way to translate quantitative biomarker data 
to quantitative exposure levels may be through the use of 
PBK modelling. Anatomical features, and physiological 
and biochemical processes control the ADME of chemicals, 
including those present naturally in food, or those introduced 
during manufacturing, processing or cooking. PBK mod-
els are one form of biokinetic models historically used by 
the exposure science, toxicology, risk assessment and drug 
development communities to relate external exposures to 
internal exposures or biomonitoring data (e.g. urine levels), 
or calculate external exposures from internal exposure or 
biomonitoring data. The use of PBK modelling for expo-
sure assessment has expanded to include reconstruction of 
exposures. In this particular use, the full available under-
standing of the biokinetics of a compound, from absorption 
to a particular exposure biomarker such as a urine or blood 
concentration is used to convert a biomarker level into an 
exposure level. For example, for bisphenol A, single spot 
urine levels can be used to estimate oral exposures by repeat-
edly running the published PBK model until an exposure 
level is found that leads to the measured urinary level. This 
approach has been used for other compounds as well (Loui-
sse et al. 2016). Overall, the value of PBK and other bioki-
netic modelling approaches for use in exposure assessment 
should not be overlooked in favour of only experimental 
methods. PBK models, through their direct representation 
of kinetic processes and the normal linkages between target 
sites of exposure and tissues and biofluids that are com-
monly or increasingly used for biomonitoring (hair, nails, 
blood, urine, sweat) are the most effective means of integrat-
ing exposure data from these disparate sources and linking 
them to levels of exposure. With respect to the process-
related contaminants of the present review the overview 
presented revealed that for acrylamide, furan and acrolein 
PBK models relating external dose levels to biomarker levels 
have been developed. So far, however, these models have 
not been used for so-called reverse dosimetry, that is, to use 
the PBK model to predict exposure levels, based on levels 
of the respective biomarkers. Clearly such approaches ena-
bling the description of quantitative relationships between 
biomarker levels and exposure levels are essential to further 
develop the field of biomarker-based exposure assessment 
and PBK models are expected to play an important role in 
this methodology, being perhaps more suitable than defining 
mathematical correlations without including the underlying 
kinetics. At the present state of the art significant challenges 
remain for validating the respective biomarkers of dietary 
exposure to the different process-related contaminants, and 
PBK models can be of use in this context.
Duplicate diet studies
Whatever method is used to define the required correlations 
between external exposure levels and biomarker levels it is 
of importance to take into account that intrinsic reactivity 
and volatility resulting in evaporation and other losses upon 
preparation of the food hamper the exposure assessment and 
thus also the definition and/or validation of the respective 
correlations. To solve this issue to the best possible extent 
and base the correlations to be defined on the quantification 
of contaminants in the products as “consumed” and not as 
“produced”, future studies should include so-called dupli-
cate diet studies. A duplicate diet study is a study in which 
human subjects consume the test diet, but also a duplicate 
portion of all food as prepared, served and consumed is 
made available for chemical analysis. Performing duplicate 
diet studies allow to exactly measure the dietary intake of 
a given process related contaminant and to compare this 
with the urinary output of appropriate metabolites that allow 
biomarker-based dosimetry. EFSA recommended that in 
order to improve the exposure assessment of acrylamide, 
duplicate diet studies be conducted and that data on urinary 
metabolite levels be collected from individuals participating 
in such studies for the purpose of validating the biomark-
ers (EFSA 2015). Of the process-related contaminants con-
sidered in the present overview such duplicate diet studies 
were only performed for acrylamide (Ruenz et al. 2016) but 
were so far not yet used to define quantitative relationships 
between external dose levels and biomarker levels detected, 
that would allow predicting external dose levels based on 
detected biomarker concentrations. A factor complicating 
the definition of these relationships, even when performing 
duplicate diet studies appears to be the possible endogenous 
formation of the process-related contaminants.
Endogenous formation of process‑related 
contaminants
Observations in animal studies and in human intervention 
studies under highly controlled conditions have been per-
formed. Minimizing background exposure in these stud-
ies revealed that the process-related contaminants under 
investigation may also be formed endogenously. Clearly 
this seriously hampers development of methods for expo-
sure assessment based on biomarker quantification, espe-
cially in the low dose range where the contribution from 
endogenous formation may be significant when compared 
to the contribution from an external source. At the present 
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state-of-the-art experiments are needed to better define the 
endogenous pathways leading to endogenous formation of 
the different biomarkers, the actual levels formed as well 
as influences of inter-individual variation and external fac-
tors on this endogenous formation. Adequate definition of 
these endogenous pathways and the resulting levels of bio-
markers may be an important prerequisite for the future risk 
assessment of process-related contaminants especially when 
the levels of endogenous formation would be in the range 
of what is expected to result from levels of normal dietary 
exposure.
Although levels of DNA adducts are generally con-
sidered biomarkers of exposure rather than biomarkers 
of effect, it is of interest to consider whether dose levels 
that result in DNA adduct levels within or even below 
the endogenous background levels would raise a con-
cern. This comparison could even be extended to levels 
of related DNA adducts to fully appreciate the relevance 
of the respective biomarker levels in risk assessment. For 
example the data reviewed above on acrylamide DNA 
adduct formation revealed that upon single oral AA appli-
cation in the dose range up to 100 µg/kg bw to rats the 
resulting tissue DNA adduct levels are considerably lower 
than reported for human background levels of structurally 
related N7-dG adducts (Wu et al. 1999; Cheng et al. 2010; 
Watzek et al. 2012a). Furthermore, a PBK study on acr-
olein revealed that at realistic dietary intake, the predicted 
formation of acrolein-DNA adducts in the liver is pre-
dicted to be orders of magnitude lower than endogenous 
background levels of structurally similar 1,N2-exocyclic 
deoxyguanosine adducts observed in disease free human 
liver (Kiwamoto et al. 2015).
Confounding factors
In addition to the endogenous formation of the process-
related contaminants, the overview presented also revealed 
other important confounding factors when considering 
the use of biomarkers to define external exposure levels. 
These include the fact that increases in the same biomarker 
may result from exposure to more than one contaminant. 
For example DHPMA is a common urinary metabolite of 
2-MCPD, 3-MCPD, glycidol and epichlorohydrin (Eckert 
et al. 2010). This may point at the need for grouping of 
biomarkers and related exposures especially when the bio-
marker indicates at a specific biological potential or adverse 
effect. Also the smoking status of human subjects has been 
found to affect biomarkers of for example acrolein, acryla-
mide, furan and glycidyl ester exposure (Landin et al. 1997; 
Grill et al. 2015). In addition, inter-individual differences 
in both endogenous formation and in metabolic pathways 
leading to biomarker formation upon external exposure need 
to be taken into account when considering extrapolation of 
biomarker levels to external dose levels. Incorporation of 
Monte Carlo based modelling approaches to generate dis-
tributions of exposure rather than exact exposure values 
may prove a valid way forward to take these aspects into 
account. Especially combining Monte Carlo modelling with 
PBK modelling may prove a way forward to deal with inter-
individual differences. The consequences of variability in 
those parameters that highly influence the conversion of a 
biomarker level to external dose values by PBK modelling 
can be evaluated by Monte Carlo modelling.
Different types of biomarkers
The present review provides also a clear overview of the 
different types of biomarkers that can be defined and quanti-
fied including urinary, blood or tissue derived biomarkers. 
Future studies need to address the relationships between the 
different biomarkers to a further extent. Current data indicate 
that urinary biomarkers like mercapturic acids may be rel-
evant to monitor short term exposure while blood and tissue 
biomarkers may better reflect longer term exposure. Thus, 
haemoglobin adducts would be more suitable than urinary 
mercapturic acids as chronic exposure biomarkers. How-
ever, haemoglobin adducts, including for example diHOPr-
Val, cannot be used as tissue biomarkers for assessing target 
organ or tissue exposure levels. For cancer risk assessment, 
tissue biomarkers such as DNA adducts in target tissues are 
superior to haemoglobin adducts. Including more than one 
biomarker may facilitate discrimination between endog-
enous and external levels of exposure and or short and long 
term exposure. Thus, as an example the combined analysis 
of DHPMA, being an urinary biomarker for exposure to both 
3-MCPD and glycidol, and haemoglobin adducts, which are 
not considered 3-MCPD biomarkers, may lead to more pre-
cise evaluation of glycidyl ester exposure in human covering 
short and long term exposures.
Clearly also new technologies for biomarker development 
are emerging and could be used for exposure assessment. 
There are three areas of development that are particularly 
relevant to biomonitoring for food process contaminants: 
novel matrices, non-targeted analytical chemistry (metab-
olomics), and computational exposure assessment. Con-
ventional biomonitoring has historically focused on easily 
accessible bio-fluids, principally urine and blood. Recently, 
interest has grown in the use of other matrices that offer 
specific benefits. Hair, nails and baby teeth for example, 
can accumulate chemicals over time, providing an average 
exposure level for a longer duration. In addition, where these 
matrices can be sectioned, there is hope that exposure his-
tory can be reconstructed. The field of metabolomics, as it 
pursues global mapping of small organic molecule metabo-
lites, has produced significant advancements in sensitivity, 
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the breadth of chemical space, sample throughput, and sup-
porting methodologies for identifying unknown analytical 
features. These approaches are equally applicable to food 
chemicals and their degradation products or metabolites. 
Of particular relevance to biomonitoring of food contami-
nants is the ability to survey for hundreds of compounds 
simultaneously, and possibly identify previously unknown 
metabolites of important compounds that may serve as better 
biomarkers of exposure.
Computational exposure science has a long history, but 
recent advancements and new applications may be impor-
tant adjunct approaches to traditional biomonitoring. Of 
particular relevance are approaches that link production/
usage levels, physical chemistry, and usage patterns to esti-
mate human external exposure, then apply biokinetic mod-
els to estimate biomarker levels in blood or urine. These 
approaches can be used to estimate biomarker levels, human 
exposure and help guide decisions on whether or not bio-
monitoring is feasible. There are opportunities to adapt these 
approaches to specific use scenarios, for example calculating 
exposures to chemicals that would result from a particular 
use (a new can liner) or a new process (heating, etc.).
Human data
A final issue to consider that is important for future develop-
ments in the field of biomarker-based exposure assessments 
is the availability of human data and models that apply to 
human exposure. At the current state of the art human data 
are needed to validate biomarkers, and validate PBK or other 
models that link levels of biomarkers to external exposure 
levels in a quantitative way. Including biomarker analysis 
in future human studies would already greatly advance the 
data base needed for further development of this approach. 
Also of great importance is the establishment of a reliable 
database on human background data, encompassing a broad 
range of biomarkers linked to exposure to process-related 
contaminants. Methodology to monitor an ever increasing 
spectrum of such biomarkers of endogenous formation of 
the reactive compounds in human body fluids and tissues is 
already in hand (adductomics). It is crucial to enlarge and 
enrich this database in order to better put into human health 
perspective the effects of exposure to a given dietary process 
related contaminant.
Conclusions
From the overview presented it becomes clear that the field 
of complementary approaches to exposure assessment of 
process-related contaminants in food by biomarker moni-
toring is still under development. The current state of the 
art as well as the existing data gaps and challenges for the 
future were defined. They include (1) definition of correla-
tions between external exposure and levels of the respective 
biomarkers preferably for the human situation, using PBK 
modelling and duplicate diet studies; (2) elucidation of the 
possible endogenous formation of the process-related con-
taminants and the resulting biomarker levels; (3) the influ-
ence of inter-individual variations and how to include that 
in the biomarker-based exposure predictions; (4) the correc-
tion for confounding factors; (5) the value of the different 
biomarkers in relation to exposure scenarios and risk assess-
ment, and (6) the possibilities of novel methodologies. In 
spite of these challenges it can be concluded that biomarker-
based exposure assessment provides a unique opportunity to 
more accurately assess consumer exposure to process-related 
contaminants in food and thus better inform the risk assess-
ment of the exposure to these contaminants.
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